Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Derek LaPlaca
Observed name:
D. LaPlaca
Institution:
Syros Pharmaceuticals (United States)
Observed institution:
Syros Pharmaceuticals (United States)
ORCID:
0000-0002-8513-2445
Observed ORCID:
0000-0002-8513-2445
OpenAlex ID:
A5034081189
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
2020
·
Candice Alleyne
, Rupesh P. Amin
, et al.
·
Journal of Medicinal Chemistry
·
138
Combination of CDK12 inhibition and olaparib enhances genomic instability in cancer models
2022
·
S. Alnemy
, N. Rajagopal
, et al.
·
European Journal of Cancer
Modeling of cell cycle response to cyclin-dependent kinase 12 (CDK12) inhibition
2022
·
S. Stein
, L. Martial
, et al.
·
European Journal of Cancer
PDF
Abstract 5393: An oral and selective CDK12 inhibitor demonstrates robust anti-tumor activity
2022
·
Shan hu
, David Moebius
, et al.
·
Cancer Research
Show more works
View as search
Works count:
4
Citation count:
138
H-index:
1
I10-index:
1
Year
Topic
Type
